EUROPENACURRICULUM VITAE

Reso ai sensi degli artt. 46 e 47 del DPR 28 dicembre 2000, n. 445 secondo forma di
DICHIARAZIONE SOSTITUTIVA DI CERTIFICAZIONE – DICHIARAZIONE SOSTITUTIVA DI ATTO DI NOTORIETA'

PERSONAL DATA

Name		[redacted]
Address		[redacted]
Date and Place of Birth		[redacted]
Nationality		[redacted]
E-mail		[redacted]
Phone		[redacted]

ESPERIENZE PROFESSIONALI

Esperienze lavorative		
• Date		***Marzo 2020 – ad Oggi Dirigente Medico Presso AORN A . Cardarelli*** ***Febbraio 2020 ad Oggi: Infettivologo Referente Unità di Crisi COVID19 Regioen Campania*** ***Ottobre 2019 – ad Oggi:*** *Referente presso SORESA per Programma Europeo VAP (Polmoniti associate a Ventilatori) Nell'mabito progetto EURIPHI* ***Gennaio 2018- Ad Oggi*** *Componente del Tavolo Tecnico Regionale Regione Campania nell'ambito antimicrobialStewardship delle Infezioni ospedaliere – PNCAR* ***Gennaio 2015 ad Oggi***: External Clinician presso Expert Directory del eCDC (European Center for Disease Control) dal 1/1/2015 ***Gennaio 2013 – Dicembre 2015:*** *Referente Italiano pre FDA Dipartimento Epatiti e Patologie Ifnattive Emergenti* ***Gennaio 2011 – Ad Oggi*** *Consulente Infettivologo Comitato Infettivologico Ospedaliero con delibera AORN A CARDARELLI n500 Agosto 2013 e successive modifiche* ***Giugno 2009- Aprile 2019***, *Specialista Ambulatoriale Hospital D. Cotugno of Naples (AORN Ospedali dei Colli), Regional Center for Infectious Disease (contratto di Specialista Ambulatoriale a tempo indeterminato)* ***Maggio 2019 ad Oggi*** *Dirigente Medico Hospital D. Cotugno of Naples (AORN Ospedali dei Colli), Regional Center for Infectious Disease* ***January 2007-June 2009:*** *Dirigente Medico consulente Infettivologo con contratto di collaborazione professionale presso Centro Trapianti Fegato "A.Cardarelli Hospital" Naples, Italy* ***Dicember 2006- December2009***: *Contrattista Dirigent eMedico presso Seconda Università Studi di Napoli per gestione Assistenza domiciliare pazienti HIV* ***Febraio 2005- Febraio 2018*** *vResearch Fellow Liver Unit King's College Hospital of London*
Posizione lavorativa attuale		Dirigente Medico Malattie Infettive AORN A. Cardarelli
Ospedale/Università		AORN A. Cardarelli, Via Antonio Cardarelli 9, Napoli
Istituzione Pubblica o Privata		Pubblica

TITOLI ACCADEMICI

Laurea – Diplomi- Dottorati		
• Data		[27/07/2000] Università degli Studi di Napoli Federico II • Laurea in Medicina e Chirurgia (MD Diploma) • Votazione/Qualification 110/110 • Diploma Ecografia internistica SIUMB 25/06/2002 (Ultrasound Medicine Diploma) • Votazione/Qualification 70/70

		• Specializzazione Malattie Infettive - Infectious Disease Specialty 03/11/2005 • Votazione/Qualification 70/70 cum summa laude • Dottorato di Ricerca Microbiologia ed Immunologia Medica – Medical Microbiology and Immunology PhD June 2012
• Università		MD and Specialty Degree at Federico II Medical School Universityof Naples PhD at TorVergata University of Rome
• JOB SKILLS e Attività Lavorative Istituzionali		Viral Hepatitis, Autoimmune Hepatitis, Infectious Disease, Hospital Acquired Infection Control, Antimicrobial Stewardship, eLearning in Infectious Disease, Abdominal Infection, Infection after Major Abdominal Surgery, Hepatology, Hepatologyin ICU, Infectious Disease in ICU, Liver transplanted patients management, Drug to Drug interaction in Antibiotic Treatment and Immunosuppression therapy, HIV management, mobileHealth Medicine in Infectious Disease and Chronic illness – mobileHealth application for Social Behavior analysis of patients with chronic illness- mHealth and eHealth App development for Infectious DIseaseand Chronic Illness *Since 2012* Lead Infectious Disease Member of CIO (Comitato Infezioni Ospedaliere, con delibera n 300 AORN A. Cardarelli Since 2015 Infectious Disease Lead Consultant of Antimicrobial Stewardship at Hospital Antonio Cardarelli – Regional Center for General Surgery, Liver Transplant Center and Internal Medicine of South of Italy. *Since 2013 Referent of FDA in Italy at Hospital Dei Colli for the study of Acute and Chronic Hepatitis and Emerging Pathogens* *Since 2017 Member of Regional Board of Antimicrobialstewardship and Hospital infection* *Since February 2020 Componente COVID19 TASK FORCE* *2017 Referente Regione Campania quale Medico Infettivolgoo nel protocollo d'intesa Ministero della Difesa- Regione Campania* Gennaio 2021 Componente Commissione PDTA Regione Campania Gennaio 2021 Coordinatore Tavolo Tecnico Antimicrobialstewardship Regione campania Gennaio 2021 Referente Regionale PNCAR Gennaio 2021 Componente commissione PNP (Piano nazionale Prevenzione) Gennaio 2021 Componente PanFLu 2021-2023 Giugno 2021 Componente Gruppo Operativo DiSpatch (*epiDemic Intelligence, Scenari Pandemici, vAluTazione rischi)* in ambito Commissione Salute Nazionale Gennaio 2021 Referente Scientifico *Progetto AGENAS- Cardarelli nell'ambito CCM 2020- "COVID-19 modelli organizzativi per l'efficientamento delle attività di contrasto all'emergenza"*
• Specialità e Dottorati		Infectious Disease – Medical Microbiology and Immunology
• Resident Training		Four

Congressi in qualità di Relatore		**SIMIT** (Italian Society of Infectious Disease) Annual meeting 2005: Oral Presentation - Role of CD4+ T cell subsets activity in Chronic Hepatitis C **AASLD 2005**: Posters – President Choice "Treg Cells during acute Hepatits C" **DDW 2005**: Posters – Role of T-cell subsets in HCV infection **BASL Annual meeting 2006**: Oral Presentation – "CD4+/CD25+ T cells suppress autologous CD4+/CD25- lymphocytes secreting granzyme B during chronic hepatitis C" **SIMIT** (Italian Infectious Disease Society) Annual meeting 2006 :Oral Presentation -" Treg Cells suppress autologous CD+/CD25- by Granzime B" AASLD 2006: Posters **DDW 2006**: Posters **APASL Annual meeting 2007**: Oral Presentation:" CD4+/CD25+ T cells suppress CD4+/CD25- lymphocytes and secrete granzyme B during chronic hepatitis C" and "HCV recurrence after OLTx:has it the same regulatory network of acute hepatitis C?"

		BASL Annual meeting 2007: Oral Presentation: "Evidence of HCV-specific CD4+ T cells interferon gamma (IFN-γ) positive cells in healthy care workers of Infectious diseases department" **ESOT Annual meeting 2007**: Oral Presentation: "Evidence of liver histological alterations in apparently healthy individuals evaluated for LDLT" – **Poster:**" Calcineurin Inhibitors Effects On Immune System And On Hcv Recurrence Within Six Months After Liver Transplantation" **ILTS Annual Meeting 2008:** Granzyme B correlates with HCV viral recurrence. **Oral Presentation** **ILTS Annual Meeting 2009:** *Effect on HCV-antigen specific PBMC response by calcineurin antagonists in liver transplanted patients with viral recurrence***OralPresentation** **ILTS Annual Meeting 2010:** *FK Stimulation of HCV-Specific and Non Specific PBMC of Patients on Waiting List To Evaluate and Tailor Immunosuppression before OLTx.* **Poster Presentation** **ILTS Annual Meeting 2011** **Oral Presentation** **ESOT Glasgow 2011**:" *Liposomal Amphotericin B prophylaxis in high risk liver transplanted patients*" **ILTS 2012: Poster Presentation** **TTS 2012: Poster Presentation** **SISQT 2012: Oral Presentation** **SISQT 2013: Oral Presentation** **SIMIT 2013: Poster Presentation** **EACS 2013: Poster Pesentation:** *"We Take Care (WTC) a mobile app to follow-up and analyze health and social behavior of patients with Chronic viral infection"*http://www.eacs-conference2013.com/index.php?id=40 **ESCMID 2014: Oral Presentation** *"Efficacy and safety of tenofovir treatment at 240 weeks in patient with chronic HBV infection"* **ESCMID 2014:Poster Presentation** *"Probiotics for gut decolonization in high risk patients after major abdominal surgery"* SIMIT (Italian Society of Infectious Disease) 2013: www.**simit**.org/medias/352-programmaavanzato.pdf ICAR (Italian conference on AntiRetrovirals) 2014: http://www.icar2014.it/pages/acceptedAbstract/download/posterPresentation.pdf ESCMID 2015: Poster Presentation **ESCMID 2017: Oral Presentation** **ESCMID 2018: Poster Presentation** **NEUROMEETING 2014-2019: Relatore** **SIMIT 2019 Relatore** **SIARTI 2021 Relatore**
Membro Società Scientifiche		SIMIT, BASL,AASLD,ILTS,ESOT, IDSA, APASL
Campo di Attività		Infectious Disease, Hepatology, Hepatic-ICU, Infectious Disease in ICU, Liver transplanted patients management, Drug to Drug interaction in Antibiotic, Antifungal and Antiviral Treatment, Information Technology in Medical practice, mobileHealth app in patients management. Social Behaviors in subjects suffering chronic illness. *Consultant Antimicrobial Stewardhip at Infectious Disease Board AORN A. Cardarelli*
Clinical Trials ai quali ha partecipato come Investigator o Principal Investigator		Principal Investigator **Diamond Astellas** 2010-2012 (I take part in the final study design Cannes 2009) (Multicenter International Study) Principal Investigator **Lobster Roche** 2009-2011 (Multicenter International Study) Co-Investigator **Prophecys Roche** 2008-2009 (Multicenter National Study) Co-investigator **Marsilea Study Astellas** (Multicenter International Study) Research Investigator **Civacir** phase II and III Study by Biotest (I had the main role to schedule all immunological experiment and I was consultant on planning the Lab Tests to perform to assay the effect of HCV-specific Immunoglobulin against HCV (International Study) Principal Investigator on **HBV Prophylaxis after OLTx** Study (2011-2012) Monocenter Clinical Trial (extension of indication)

		Principal Investigator on **Antifungal Prophylaxis in OLTx** (2008-2012) Monocenter Clinical Trial (extension of indication) Principal Investigator **HBV Prophylaxis with Immunoglobulin by Grifols** (2010) Monocenter Clinical Trial Principal Investigator **International Study** Co-Principal Investigator Studio **MK4482-002 – COVID19- MSD** CO-investigator **International Study on Favipavir use in COVID19 – FujiPharma - JP**
CME Credit/year		110/yr – ResearchGate Score 38.96- Impact Point 310 – H-Index 20 (2000-2021)

PROFESSIONAL SKILLS

Management of Health Care Workers in Clinical and Research Field.
Consultant for Antimicrobial Stewardship at Infectious Disease Board – AORN A. Cardarelli
Coordinator of Clinical Trial and Research Project
Communication skills acquired as Teacher during last 5 years in several National and International Courses
Referee of Several high impacted Journals:" JID, CID, Hepatology, Gastroenterology, GUT, Journal Hepatology and Gastroenterology, Scandinavian Journal Infectious Disease, Scandinavian Journal Immunology, Scandinavian Journal Gastroenterology, American Journal Transplantation, Transplantation, Journal of Translational Medicine, AIDS, JAIDS

LINGUA NATIVA		ITALIANO
ALTRE LINGUE		ENGLISH - GOOD
• Reading ability		EXCELLENT
• Writing ability		GOOD
Computer Skill		EXCELLENT

SHORT CLINICAL EXPERIENCES RESUME		Since 2006 Assistant Infectious Disease Consultant at Liver Transplant Center AORN A. CARDARELLI. In particular, I have been involved in pre-and post-OLTx management of the patients, including early and late infectious disease in ICU or WARD stay as well as at outpatient clinic. Mainly I was focused on Fungal, Bacterial and Viral Infections as well as Drug to Drug interaction in Antibiotic, Antifungal and Antiviral Treatment and related safety. Further I managed immunosuppressive therapy and drug to drug interactions as well as adverse effects in immunosuppressive drugs. From 2011 Infectious Disease Consultant for Antimicrobial Stewardship at Infectious Disease Board at A. Cardarelli Hospital. Recently, in the last 3 years, I have been engaged in mobileHealth development and research aimed to improve patients follow-up and to analyze social behavior of subjects suffering chronic illness.

Attached		2

WEB-LINK		https://www.researchgate.net/profile/Alessandro_Perrella?ev=hdr_xprf it.linkedin.com/in/alessandroperrella/ https://orcid.org/0000-0003-2812-8500
REFERENCES		References: Prof R. Cauda – Director Malattie Infettive Polidinico Gemelli di Roma Prof D. Vergani – Director Liver Unit- King's College Medical School of London Prof F. Piccinino- Director Malattie Infettive Seconda Università Studi di Napoli Prof A. Marcos – Abdominal Transplant Surgeon, Pitsbugh USA Dr O. Cuomo - Centro Liver Transplant Center CLSE-CTF AORN A Cardarelli, Napoli Dr F. Calise - Centro Liver Transplant Center CEB-CTF AORN A. Cardarelli, Napoli Dr C. Esposito - Hepatic ICU AORN A. Cardarelli, Napoli Dr. C. Russo – Infectious Disease Board AORN A.Cardarelli, Napoli Dr F. Paradiso – Medical Director AORN A. Cardarelli Prof A. Quaglia – Director Histopahtology Liver Unit King's College Medical School of London Prof. G.Mieli Vergani- Director Pediatric Unit King's College Medical School of London Prof G Kaplan – Director Dpt Emerging Pathognes and Viral Hepatitis –FDA- USA

Pubblicazioni Scientifiche Rilevanti Impattate dal 2000 ad oggi escludendo Atti congressi	**Perrella A**, Tarantino G, Borgia G, Conca P, Sorrentino P, Ragucci P, Vecchione R, Perrella O. Cytokine network during NASH and possible treatment selection.Hepatology. 2003 Aug;38(2):530 Sorrentino P, Tarantino G, Conca P, Ragucci P, **Perrella A**. Abnormally high resistive index of central retinal artery by ultrasound color Doppler in patients with viral chronic liver disease: correlation with worsening liver staging. Ultrasound Med Biol. 2004 May;30(5):599-604.PMID: 15183224 [PubMed - indexed for MEDLINE] Tarantino G, Sorrentino P, Conca P, **Perrella A**, Ragucci P, Perrella O. Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study.Liver Int. 2003 Dec;23(6):413-9 **Perrella A**, Borgia G, Reynaud L, Borrelli F, Di Sirio S, Grattacaso S, Perrella O. Hepatitis C and diabetes mellitus: what is the metabolic pathway?Gastroenterology. 2004 Oct;127(4):1279-80 Sorrentino P, Tarantino G, **Perrella A**, Micheli P, Perrella O, Conca P. A clinical-morphological study on cholestatic presentation of nonalcoholic fatty liver disease. Dig Dis Sci. 2005 Jun;50(6):1130-5 **Perrella A**, Borgia G, Guida GM, Graf M, Gnarini RM, Viola C, Atripaldi L, Sbreglia C, Perrella O. Human immunodeficiency virus and subtype 1B hepatitis C virus: more similarities than differences in T-helper subsets.J Gastroenterol Hepatol. 2005 Aug;20(8):1310-2. Perrella O, Sbreglia C, Perrella M, Spetrini G, Gorga F, Perrella M, **Perrella A**, Atripaldi L, Carrieri P. Interleukin-10 and tumor necrosis factor-alpha: model of immunomodulation in multiple sclerosis. Neurol Res. 2006 Mar;28(2):193-5 **Perrella A** et al. Flow cytometry assay of myeloid Dendritic Cells (mDCs) in peripheral blood during acute hepatitis C: possible pathogenetic mechanisms. World Journal Gastroenterol 2006:21;1105-1109 **Perrella A**, Borgia G, Perrella O. Immune system homeostasis during acute hepatitis C: viral escape or T-cell regulation? Hepatology. 2004 Nov;40(5):1229. **Perrella A** et al. Elevated CD4+/CD25+ T cell frequency and function during acute hepatitis C presage chronic evolution. Gut 2006;55;1370-1371 **Perrella A**, Vitiello L, Atripaldi L, Sbreglia C, Grattacaso S, Bellopede P, Patarino T, Morelli G, Altamura S, Racioppi L, Perrella O.Impaired function of CD4+/CD25+ T regulatory lymphocytes characterizes the self-limited hepatitis A virus infection. J Gastroenterol Hepatol. 2008 23(7 Pt 2):e105-10 **Perrella A**, Grattacaso S, Gnarini M, D'Antonio A et al., Increase of granzyme-B positive cells in ascitic fluid of patients with spontaneous bacterial peritonitis. Hepatol Res. 2008 Apr;38(4):410-4 **A. Perrella**, C. Sbreglia, A. D'Antonio, L. Atripaldi, O. Perrella. Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a HCV-RNA decrease and a Th1 network boost in HIV/HCV-coinfected patients. Clin Microbiol And Infect Dis. 2009 Cuomo O, **Perrella A**, Arenga G. Model for End-Stage Liver Disease

(MELD) score system to evaluate patients with viral hepatitis on the waiting list: better than the Child-Turcotte-Pugh (CTP) system? Transplant Proc. 2008 Jul-Aug;40(6):1906-9.

Cuomo O, **Perrella A**, Pisaniello D, Marino G, Di Costanzo G. Evidence of liver histological alterations in apparently healthy individuals evaluated for living donor liver transplantation. Transplant Proc. 2008 Jul-Aug;40(6):1823-6.

Perrella A, Arenga G, Pisaniello D, Rampone B, Di Costanzo GG, Atripaldi L, Esposito C, Di Florio E, Perrella O, Cuomo O. Elevated CD4+/CD25+ T-cell frequency and function during hepatitis C virus recurrence after liver transplantation. Transplant Proc. 2009 Jun;41(5):1761-6.

Perrella A, Grattacaso S, d'Antonio A, Atripaldi L, Sbreglia C, Gnarini M, Conti P, Vecchiet J, Perrella O. Evidence of hepatitis C virus-specific interferon gamma-positive T cells in health care workers in an infectious disease department. Am J Infect Control. 2009 Jun;37(5):426-9

Morelli G, **Perrella A**, Sbreglia C, Bellopede P, Riccio V, Monaco A, Perrella O. Antiviral therapy in acute viral hepatitis B: why and when. Infect Agent Cancer. 2009 Apr 1;4:5

Sorrentino P, Terracciano L, D'Angelo S, Ferbo U, Bracigliano A, Tarantino L, **Perrella A**, Perrella O, et al. Oxidative stress and steatosis are cofactors of liver injury in primary biliary cirrosi. J Gastroenterol. 2010 Apr 15.

Perrella O, Cuomo O, Sbreglia C, Monaco A, Gnarini MR, Gentile B, Perrella M, **Perrella A** IL-18 and interferon-gamma in HCV-related hepatocellular carcinoma: a model of interplay between immune status and cancer. J Biol Regul Homeost Agents. 2009 Oct-Dec;23(4):251-8

Perrella A, Sbreglia C, Atripaldi L, Esposito C, D'Antonio A, Perrella O. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin. Scand J Gastroenterol. 2010;45(2):250-5

Perrella A, Sbreglia C, D'Antonio A, Atripaldi L, Perrella O. Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a HCV-RNA decrease and a Th1 network boost in HIV/HCV-coinfected patients. Clin Microbiol Infect. 2010 Jun;16(6):676-8

Perrella A, Esposito C, Ioia G, Campanella L, Taglialatela D, Cuomo O. Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience. Transplant Proc. 2010 May;42(4):1226-8.

Preservation of Nutritional-status in Patients with Refractory Ascites due to Hepatic Cirrhosis who are Undergoing Repeated Paracentesis.Sorrentino P, Castaldo G, Tarantino L, Bracigliano A, **Perrella A**, Perrella O, Fiorentino F, Vecchione R, D'Angelo S.J Gastroenterol Hepatol. 2011 Dec 6. doi: 10.1111/j.1440-1746.2011.07043.x

Endometrial polyps in infertile patients: do high concentrations of interferon-gamma play a role?Mollo A, Stile A, Alviggi C, Granata M, De

Placido G, **Perrella A**, d'Antonio A, Cicinelli E.Fertil Steril. 2011 Nov;96(5):1209-12. Epub 2011 Aug 26.

Manangeeswaran M, Jacques J, Tami C, Konduru K, Amharref N, Perrella O, Casasnovas JM, Umetsu DT, Dekruyff RH, Freeman GJ, **Perrella A**, Kaplan GG. Binding of Hepatitis A Virus to its Cellular Receptor 1 Inhibits T-Regulatory Cell Functions in Human Beings.Gastroenterology. 2012 Mar 16

Avolio AW, Agnes S, Cillo U, Lirosi MC, Romagnoli R, Baccarani U, Zamboni F, Nicolini D, Donataccio M, **Perrella A**, Ettorre GM, Romano M, Morelli N, Vennarecci G, de Waure C, Fagiuoli S, Burra P, Cucchetti A. http://www.D-MELD.com, the Italian survival calculator to optimize donor to recipient matching and to identify the unsustainable matches in liver transplantation.Transpl Int. 2012 Mar;25(3):294-301. doi: 10.1111/j.1432-2277.2011.01423.x. Epub 2012 Jan 23.

Sorrentino P, Castaldo G, Tarantino L, Bracigliano A, **Perrella A**, Perrella O, Fiorentino F, Vecchione R, D' Angelo S. Preservation of nutritional-status in patients with refractory ascites due to hepatic cirrhosis who are undergoing repeated paracentesis.. J Gastroenterol Hepatol. 2012 Apr;27(4):813-22. doi: 10.1111/j.1440-1746.2011.07043.x.

Avolio AW, Agnes S, Cillo U, Lirosi MC, Romagnoli R, Baccarani U, Zamboni F, Nicolini D, Donataccio M, **Perrella A**, Ettorre GM, Romano M, Morelli N, Vennarecci G, de Waure C, Fagiuoli S, Burra P, Cucchetti A.http://www.D-MELD.com, the Italian survival calculator to optimize donor to recipient matching and to identify the unsustainable matches in liver transplantation.Transpl Int. 2012 Mar;25(3):294-301

Perrella A, Lanza AG, Santaniello W, Pisaniello D, Dicostanzo G, Calise F, Amato G, Marcos A, Cuomo O. Telbivudin as prophylaxis for hepatitis B virus recurrence after liver transplantation: a case series in single-center experience.Transplant Proc. 2012 Sep;44(7):1986-8.

Perrella A, Esposito C, Pisaniello D, D'Alessio L, Perrella O, Marcos A, Cuomo O. Role of liposomal amphotericin B prophylaxis after liver transplantation compared with fluconazole for high-risk patients. impact on infections and mortality within one year.Transplant Proc. 2012 Sep;44(7):1977-81

Durante-Mangoni E, Maiello C, Limongelli G, Sbreglia C, Pinto D, Amarelli C, Pacileo G, **Perrella A**, Agrusta F, Romano G, Marra C, Di Giambenedetto S, Nappi G, Utili R. Management of immunosuppression and antiviral treatment before and after heart transplant for HIV-associated dilated cardiomyopathy. Int J Immunopathol Pharmacol. 2014 Jan-Mar;27(1):113-20. PubMed PMID: 24674686.

Perrella A, D'Antonio A, Sbreglia C, Sorrentino P, Conca P, Atripaldi L, Conti P, Perrella O. CD4+/CD25+ T cells suppress autologous CD4+/CD25- lymphocytes and secrete granzyme B during acute and chronic hepatitis C. Pathog Dis. 2014 Jun 2. doi: 10.1111/2049-632X.12190

Perrella A, Lanza AG, Pisaniello D, DiCostanzo G, Calise F, Cuomo O Telbivudine prophylaxis for hepatitis B virus recurrence after liver transplantation improves renal function. Transplant Proc. 2014 Sep;46(7):2319-21.

Perrella A, C Russo, C.Esposito, A.Giuliani, P.Saturnino Infection Control in a Far Far Away Galaxy: New and Alternative Learning Tool from Popular Culture to Improve the Antimicrobial Stewardship. North Am J Med Sci N Am J Med Sci. 2015 May;7(5):236-7. doi: 10.4103/1947-2714.157639

Perrella A and Morfino V. WTC (WE TAKE CARE) EXPERIMENTAL SMARTPHONE APP TO FOLLOW-UP AND TAKE CARE OF PATIENTS WITH CHRONIC INFECTIOUS DISEASE: WHICH IMPACT ON PATIENTS LIFE STYLE?Global Sustainability Inside and Outside the Territory: 107-112. DOI: 10.1142/9789814651325_0009

Perrella A, Esposito C, Amato G, Perrella O, Migliaccio C, Pisaniello D, Calise F, Cuomo O, Santaniello W. Antifungal prophylaxis with liposomal amphotericin B and caspofungin in high-risk patients after liver transplantation: impact on fungal infections and immune system. Infect Dis (Lond). 2016 Feb;48(2):161-6. doi: 10.3109/23744235.2015.1100322

Nappi A, **Perrella A**, Bellopede P, Lanza A, Izzi A, Spatarella M, Sbreglia C. Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist. Infect Agent Cancer. 2017 Feb 7;12:12. doi: 10.1186/s13027-017-0119-8

Cleo Study Group, Ascione A, Adinolfi LE, Amoroso P, Andriulli A, Armignacco O, Ascione T, Babudieri S, Barbarini G, Brogna M, Cesario F, Citro V, Claar E, Cozzolongo R, D'Adamo G, D'Amico E, Dattolo P, De Luca M, De Maria V, De Siena M, De Vita G, Di Giacomo A, De Marco R, De Stefano G, De Stefano G, Di Salvo S, Di Sarno R, Farella N, Felicioni L, Firniani B, Fontanella L, Foti G, Furlan C, Giancotti F, Giolitto G, Gravina T, Guerrera B, Gulminetti R, Iacobellis A, Imparato M, Iodice A, Iovinella V, Izzi A, Liberti A, Leo P, Lettieri G, Luppinol, Marrone A, Mazzoni E, Messina V, Monarca R, Narciso V, Nosotti L, Pellicelli AM, **Perrella A**, Piai G, Picardi A, Pierri P, Pietromatera G, Resta F, Rinaldi L, Romano M, Rossini A, Russello M, Russo G, Sacco R, Sangiovanni V, Schiano A, Sciambra A, Scifo G, Simeone F, Sullo A, Tarquini P, Tundo P, Vallone A. Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. World J Hepatol. 2016 Aug 8;8(22):949-56. doi: 10.4254/wjh.v8.i22.949.

Pisapia A, Crolla E, Saglioccolo RA, **Perrella A**, Molino C. Preoperative diagnosis and surgical treatment for giant retroperitoneal liposarcoma: A case report. Int J Surg Case Rep. 2019;57:179-182.

Rinaldi L, Guarino M, **Perrella A**, Pafundi PC, Valente G, Fontanella L, Nevola R, Guerrera B, Iuliano N, Imparato M, Trabucco A, Sasso FC, Morisco F, Ascione A, Piai G, Adinolfi LE. Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience. Dig Dis Sci. 2019 Apr 1.

Perrella A, Izzi A, Punzi R, Adinolfi E, Sbreglia C, Bellopede P, Galeota Lanza A, Martucci F, Rinaldi L. Late HCC onset after direct antiviral agents therapy in patients with sustained virological response: do we need to reconsider their efficacy according to long term follow-up? Scand J Gastroenterol. 2018 Aug;53(8):1025-1026.

Perrella A, Rinaldi L, Galeota-Lanza A, Izzi A. DAAs and long-term clinical outcome in hepatitis C: the panacea for all diseases still does not exist. Am J Gastroenterol. 2018 Aug;113(8):1251.

Nappi A, **Perrella A**, Bellopede P, Lanza A, Izzi A, Spatarella M, Sbreglia C. Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist. Infect Agent Cancer. 2017 Feb 7;12:12.

Pisapia A, Crolla E, Saglioccolo RA, **Perrella A**, Molino C. Preoperative diagnosis and surgical treatment for giant retroperitoneal liposarcoma: A case report. Int J Surg Case Rep. 2019;57:179-182.

Perrella A, Izzi A, Punzi R, Adinolfi E, Sbreglia C, Bellopede P, Galeota Lanza A, Martucci F, Rinaldi L. Late HCC onset after direct antiviral agents therapy in patients with sustained virological response: do we need to reconsider their efficacy according to long term follow-up? Scand J Gastroenterol. 2018 Aug;53(8):1025-1026.

Perrella A, Rinaldi L, Galeota-Lanza A, Izzi A. DAAs and long-term clinical outcome in hepatitis C: the panacea for all diseases still does not exist. Am J Gastroenterol. 2018 Aug;113(8):1251.

Rinaldi L, Guarino M, **Perrella A**, Pafundi PC, Valente G, Fontanella L, Nevola R, Guerrera B, Iuliano N, Imparato M, Trabucco A, Sasso FC, Morisco F, Ascione A, Piai G, Adinolfi LE. Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience. Dig Dis Sci. 2019 Apr 1

Nappi A, **Perrella A**, Rinaldi L, Izzi A, Punzi R, Adinolfi LE, Sbeglia C, Bellopede P, Maddaloni A, Papa N, Spatarella M. Late HCC onset after DAAs therapy in patients with SVR: a type D ADR that requires a longer follow-up? Eur J Hosp Pharm. 2019 Jul;26(4):243-244.

Rinaldi L, **Perrella A**, Guarino M, De Luca M, Piai G, Coppola N, Pafundi PC, Ciardiello F, Fasano M, Martinelli E, Valente G, Nevola R, Monari C, Miglioresi L, Guerrera B, Berretta M, Sasso FC, Morisco F, Izzi A, Adinolfi LE. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. J Transl Med. 2019 Aug 28;17(1):292. doi: 10.1186/s12967-019-2033-x.

Rinaldi L, Nevola R, Franci G, **Perrella A**, Corvino G, Marrone A, Berretta M, Morone MV, Galdiero M, Giordano M, Adinolfi LE, Sasso FC. Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics. Cancers (Basel). 2020 May 26;12(6):1351. doi: 10.3390/cancers12061351. PMID: 32466400; PMCID: PMC7352473.

Perrella A, Trama U, Bernardi FF, Russo G, Monastra L, Fragranza F, Orlando V, Coscioni E. Editorial - COVID-19, more than a viral pneumonia. Eur Rev Med Pharmacol Sci. 2020 May;24(9):5183-5185. doi: 10.26355/eurrev_202005_21216. PMID: 32432786.

Perrella A, Esposito C, Giuliani A, Migliaccio C, Granato G, Santaniello W, Vennarecci G. Renal Safety of Liposomal Amphotericin B After Liver Transplantation. Prog Transplant. 2020 Jun;30(2):179-181. doi: 10.1177/1526924820913504. Epub 2020 Apr 10. PMID: 32274972.

Perrella A, Carannante N, Berretta M, Rinaldi M, Maturo N, Rinaldi L. Novel **Coronavirus 2019 (Sars-CoV2):** a global emergency that needs new approaches? Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2162-2164. doi: 10.26355/eurrev_202002_20396. PMID: 32141586.

Marrone A, Franci G, **Perrella A**, Nevola R, Chianese A, Adinolfi LE, Sasso FC, Rinaldi L. Editorial - HCC in HCV patients and the direct acting antivirals: is there really a link? Eur Rev Med Pharmacol Sci. 2020 Jan;24(2):983-987. doi: 10.26355/eurrev_202001_20084. PMID: 32017007.

Welte T, Len O, Muñoz P, Romani L, Lewis R, **Perrella A**. Invasive mould infections in solid organ transplant patients: modifiers and indicators of disease and treatment response. Infection. 2019 Dec;47(6):919-927. doi: 10.1007/s15010-019-01360-z. Epub 2019 Oct 1. PMID: 31576498

Galiero R, Pafundi PC, Simeon V, Rinaldi L, **Perrella A**, Vetrano E, Caturano A, Alfano M, Beccia D, Nevola R, Marfella R, Sardu C, Coppola C, Scarano F, Maggi P, De Lucia Sposito P, Vocciante L, Rescigno C, Sbreglia C, Fraganza F, Parrella R, Romano A, Calabria G, Polverino B, Pagano A, Bologna C, Amitrano M, Esposito V, Coppola N, Maturo N, Adinolfi LE, Chiodini P, Sasso FC; COVOCA Study Group. Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study. PLoS One. 2020 Dec 10;15(12):e0243700. doi: 10.1371/journal.pone.0243700. PMID: 33301529; PMCID: PMC7728173.

Rinaldi L, Nevola R, Franci G, **Perrella A**, Corvino G, Marrone A, Berretta M, Morone MV, Galdiero M, Giordano M, Adinolfi LE, Sasso FC. Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics. Cancers (Basel). 2020 May 26;12(6):1351. doi: 10.3390/cancers12061351. PMID: 32466400; PMCID: PMC7352473

Marrone A, Franci G, **Perrella A**, Nevola R, Chianese A, Adinolfi LE, Sasso FC, Rinaldi L. Editorial - HCC in HCV patients and the direct acting antivirals: is there really a link? Eur Rev Med Pharmacol Sci. 2020 Jan;24(2):983-987. doi: 10.26355/eurrev_202001_20084. PMID: 32017007.

Sasso FC, Pafundi PC, Caturano A, Galiero R, Vetrano E, Nevola R, Petta S, Fracanzani AL, Coppola C, Di Marco V, Solano A, Lombardi R, Giordano M, Craxi A, **Perrella A**, Sardu C, Marfella R, Salvatore T, Adinolfi LE, Rinaldi L. Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. Nutr Metab Cardiovasc Dis. 2021 Jul 22;31(8):2345-2353.

Giannattasio A, Maglione M, D'Anna C, Muzzica S, Angrisani F, Acierno S, **Perrella A**, Tipo V. Silent RSV in infants with SARS-CoV-2 infection: A case series. Pediatr Pulmonol. 2021 May 25;10.1002/ppul.25465.

Lugara M, Oliva G, Pafundi PC, Tamburrini S, Nevola R, Gjeloshi K, Ricozzi C,mbriani S, Padula A, Aprea C, Meo L, Cozzolino D, Cuomo G, Marrone A, Romano C,

		Fiorini V, Coppola MG, Corvino M, **Perrella A**, Ponti G, Nunnari G, Ranieri R, Ruosi C, Sasso FC, Adinolfi LE, Rinaldi L. Clinical application of lung ultrasound score on COVID-19 setting: a regional experience in Southern Italy. Eur Rev Med Pharmacol Sci. 2021 May;25(9):3623-3631. Orlando V, Coscioni E, Guarino I, Mucherino S, **Perrella A**, Trama U, Limongelli G, Menditto E. Drug-utilisation profiles and COVID-19. Sci Rep. 2021 Apr 26;11(1):8913. Galiero R, Pafundi PC, Simeon V, Rinaldi L, **Perrella A**, et al; COVOCA Study Group. Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study. PLoS One. 2020 Dec 10;15(12):e0243700. Rinaldi L, Nevola R, Franci G, **Perrella A**, Corvino G, Marrone A, Berretta M, Morone MV, Galdiero M, Giordano M, Adinolfi LE, Sasso FC. Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics. Cancers (Basel). 2020 May 26;12(6):1351. doi: 10.3390/cancers12061351. PMID: 32466400; PMCID: PMC7352473. Here I agree to the use of my personal CV data, for job purpose, according to European Laws on privacy. I don't give any authorizations to use my personal CV data for any other purpose. Si Autorizza al trattamento dei dati personali in accordo alle attuali normative vigenti, tuttavia non si autorizza il trattamento dei dati ai fini pubblicitari.

DICHIARAZIONE SOSTITUTIVA DI CERTIFICAZIONE (art. 46 e 47 D.P.R. 445/2000)

Il/La sottocritto/a_Alessandro Perrella_____,ai sensi e per gli effetti degli articoli 46 e 47 e consapevole delle sanzioni penali previste dall'articolo 76 del D.P.R. 28 dicembre 2000, n. 445 nelle ipotesi di falsità in atti e dichiarazioni mendaci, dichiara che le informazioni riportate nel presente curriculum vitae, redatto in formato europeo, corrispondono a verità

DATA 01/2021

FIRMA